Comparing two diabetes drugs and their effect on the eye
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study compares two types of diabetes medications (GLP-1 receptor agonists and SGLT2 inhibitors) to see how they affect blood vessels in the back of the eye over time. It may help doctors understand if one drug is better for protecting your eyes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have type 2 diabetes.
- Your doctor has decided to start you on either a GLP-1 receptor agonist or an SGLT2 inhibitor for the first time.
- You have no or only very early signs of diabetic eye disease (retinopathy) in at least one eye.
- Your blood sugar (HbA1c) level is 7.0% or higher, measured within 30 days of your eye exam.
- You have not taken a GLP-1 receptor agonist or SGLT2 inhibitor before, and you haven't had prior treatments for diabetic eye disease (like laser or injections).
- You are not pregnant, have no other serious eye diseases, and your blood pressure and kidney function are under control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether newer diabetes drugs (like SGLT2 inhibitors and DPP-4 inhibitors) can help protect the eyes of people with long-standing type 2 diabetes. The study focuses on preventing or slowing diabetic retinopathy, a common eye complication.
This study uses a special eye scan (OCTA) to look at the tiny blood vessels in the back of the eye and compares them between people with diabetes whose blood sugar is well-controlled and those whose is not. The goal is to understand how blood sugar control affects eye health in people with diabetic retinopathy.
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
This study looks at how images and other tests of the eye can help predict diabetic retinopathy, an eye problem caused by diabetes that can lead to vision loss. If you have diabetes, your eye health will be monitored closely. If you do not, you may participate as a healthy comparison.
This study follows people with type 2 diabetes to understand how diabetic retinopathy (an eye disease caused by diabetes) changes over time without treatment. It may help if you have no other eye issues causing new blood vessels and are not planning for certain eye procedures.
This study measures blood flow in the eyes and how the retina (back of the eye) uses oxygen in people with diabetes who are starting a new type of diabetes medication. Researchers want to understand how these newer medications affect blood vessels in the eyes.
Hear when a new Type 2 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.